公开(公告)号：US10287582B2

公开(公告)日：2019-05-14

申请号：US15359894

申请日：2016-11-23

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Gregory Hinkle ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Markus Warmuth ,  Wenlai Zhou ,  Ping Zhu ,  Tracy S. Zimmermann

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  C07H21/02

摘要： The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

公开(公告)号：US20170073678A1

公开(公告)日：2017-03-16

申请号：US15359894

申请日：2016-11-23

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Gregory Hinkle ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Markus Warmuth ,  Wenlai Zhou ,  Ping Zhu ,  Tracy S. Zimmermann

IPC分类号： C12N15/113 ,  A61K45/06 ,  A61K31/713

CPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  C07H21/02 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2320/31 ,  C12N2320/51 ,  C12N2320/53 ,  Y02A50/467 ,  C12N2310/3521

摘要： The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

摘要翻译： 本公开涉及使用治疗有效量的RNAi剂对HSF治疗热休克因子1（HSF1）相关疾病如癌症和病毒性疾病的方法。

公开(公告)号：US20180355362A1

公开(公告)日：2018-12-13

申请号：US16105522

申请日：2018-08-20

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Antonin De Fougerolles ,  John Diener ,  Emma Hickman ,  Gregory Hinkle ,  Stuart Milstein ,  Anne-Marie Pulichino ,  Andrew Griffin Sprague

IPC分类号： C12N15/113 ,  A61K31/713

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

公开(公告)号：US10081811B2

公开(公告)日：2018-09-25

申请号：US15661132

申请日：2017-07-27

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Antonin De Fougerolles ,  John Diener ,  Emma Hickman ,  Gregory Hinkle ,  Stuart Milstein ,  Anne-Marie Pulichino ,  Andrew Griffin Sprague

IPC分类号： C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  A61K31/713

CPC分类号： C12N15/1138 ,  A61K31/713 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2310/3515 ,  C12N2310/3517 ,  C12N2310/3521

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

公开(公告)号：US20160272979A1

公开(公告)日：2016-09-22

申请号：US15166576

申请日：2016-05-27

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Antonin De Fougerolles ,  John Diener ,  Emma Hickman ,  Gregory Hinkle ,  Stuart Milstein ,  Anne-Marie Pulichino ,  Andrew Griffin Sprague

IPC分类号： C12N15/113

CPC分类号： C12N15/1138 ,  A61K31/713 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2310/3515 ,  C12N2310/3517 ,  C12N2310/3521

摘要： The present disclosure relates to RNAi agents useful in methods of treating BetaENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

摘要翻译： 本公开内容涉及可用于使用治疗有效量的β-半乳糖苷酶治疗β-肾上腺素相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压） RNAi试剂至β-ENaC。

公开(公告)号：US12091661B2

公开(公告)日：2024-09-17

申请号：US17714272

申请日：2022-04-06

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Gregory Hinkle ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Markus Warmuth ,  Wenlai Zhou ,  Ping Zhu ,  Tracy S. Zimmermann

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  C07H21/02

CPC分类号： C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  C07H21/02 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2320/31 ,  C12N2320/51 ,  C12N2320/53 ,  Y02A50/30 ,  C12N2310/321 ,  C12N2310/3521

摘要： The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

公开(公告)号：US20220380775A1

公开(公告)日：2022-12-01

申请号：US17714272

申请日：2022-04-06

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Gregory Hinkle ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Markus Warmuth ,  Wenlai Zhou ,  Ping Zhu ,  Tracy S. Zimmermann

IPC分类号： C12N15/113 ,  A61K45/06

摘要： The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

公开(公告)号：US11261444B2

公开(公告)日：2022-03-01

申请号：US16747729

申请日：2020-01-21

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Brian Bettencourt ,  Shanthi Ganesh ,  Elizabeth George ,  Dieter Huesken ,  Stuart Milstein ,  Jonathan Solomon ,  Emily Thomas ,  Ivanka Toudjarska ,  Jennifer Tullai ,  Jan Weiler

IPC分类号： C12N15/113 ,  A61K45/06 ,  A61K31/7105 ,  A61K31/7115 ,  A61K31/712 ,  A61K31/7125 ,  A61K31/713

摘要： The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preeclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

公开(公告)号：US11091761B2

公开(公告)日：2021-08-17

申请号：US16411805

申请日：2019-05-14

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Gregory Hinkle ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Markus Warmuth ,  Wenlai Zhou ,  Ping Zhu ,  Tracy S. Zimmermann

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61P31/12 ,  A61P31/18 ,  A61P19/02 ,  A61P31/20 ,  A61P29/00 ,  A61P31/22 ,  A61K45/06 ,  C07H21/02

摘要： The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

公开(公告)号：US20180282728A1

公开(公告)日：2018-10-04

申请号：US16007517

申请日：2018-06-13

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Brian Richard Bettencourt ,  David Anton Bumcrot ,  Dieter Huesken ,  Satyanarayana Kuchimanchi ,  Stuart Milstein ,  Michael Ray Schlabach, JR. ,  Frank Peter Stegmeier ,  Markus Warmuth ,  Jan Weiler

IPC分类号： C12N15/113 ,  A61K31/713

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.